Artrya Limited is an Australia-based medical technology company. The Company is focused on commercializing its patented artificial intelligence platform. The Company is an applied artificial intelligence (AI) healthcare company, which works alongside clinicians to improve the diagnosis of coronary heart disease and develops an overview of a patient at risk. The Company develops deep learning algorithms, which allow for the prediction and prevention of acute coronary events. The Company creates an artificial intelligence (AI)-based cardiac software solution, Artrya Salix. Artrya Salix is a non-invasive diagnostic support solution to detect coronary artery disease. The cloud-based software draws on thousands of computed tomography coronary angiography (CCTA) scans to automatically detect vulnerable plaque, stenosis and other biomarkers in a patient’s cardiovascular system, all within minutes. The Company’s subsidiary includes Artra Medical IP Pty Ltd.